Buenos Aires, Argentina — The International Society for Stem Cell Application (ISSCA) announces the 11th ISSCA Symposium on Regenerative Medicine and Cellular Therapies, taking place on July 10–11, 2026, at the Hilton Buenos Aires. This edition represents a historic milestone, as it is projected to be the largest ISSCA event ever held in Argentina, reflecting more than 11 years of sustained growth, strategic alliances, and scientific leadership in the country.
Argentina has played a foundational role in ISSCA’s development across Latin America. Over more than a decade, the organization has built a strong and committed medical community through continuous education, long-term partnerships, and internationally recognized certification programs. The 2026 symposium represents the consolidation of this journey—bringing together an expanded international faculty, advanced certifications, and one of the most comprehensive scientific programs ISSCA has delivered in the region.
“Argentina has been instrumental in ISSCA’s growth in Latin America,” said Benito Novas, Founder of ISSCA.
“Reaching our 11th symposium in the country—and doing so with our largest event to date—reflects the strength of our alliances, the maturity of the medical community, and our shared commitment to advancing regenerative medicine through education and global standards.”
Argentina as a Strategic Pillar for ISSCA in Latin America
Argentina’s strong medical tradition, academic rigor, and openness to innovation have positioned the country as a reference point for regenerative, aesthetic, and integrative medicine in Latin America. ISSCA’s long-standing presence has contributed to the professionalization of these fields, supporting physicians as they integrate evidence-based regenerative therapies into clinical practice with responsibility and clinical rigor.
The 11th ISSCA Symposium reinforces Argentina’s role not only as a host country, but as a strategic pillar within ISSCA’s global and LATAM expansion, attracting physicians from across South America and beyond.
Leadership Rooted in Ethics and Clinical Responsibility
This milestone event carries special significance as Argentina is the country of origin of Dr. Andrea Lapeire, ISSCA LATAM Chapter Director and one of the organization’s most influential educators in regenerative and functional medicine. Her leadership has been central to ISSCA’s growth throughout Latin America, helping physicians navigate the evolution of modern medicine with a strong ethical foundation.
“Medicine evolves, and so does our responsibility as physicians,” said Dr. Andrea Lapeire, ISSCA LATAM Chapter Director.
“Regenerative medicine represents a natural step forward—one that allows us to respond more accurately to the complexity of each patient’s clinical history. Remaining open to this evolution is essential if we truly aim to practice medicine with integrity, responsibility, and long-term vision.”
Her perspective reflects the core values ISSCA promotes across the region: continuous education, ethical responsibility, and a commitment to offering patients solutions aligned with both scientific evidence and compassionate care.
Scientific Program and International Certifications
The two-day symposium will feature a comprehensive scientific agenda addressing key areas of regenerative medicine, including:
- Cellular and regenerative therapies
- Peptide-based clinical applications
- Aesthetic and functional regenerative medicine
- Musculoskeletal (MSK) regeneration and repair
- Longevity, inflammation control, and metabolic health
- Clinical safety, protocols, and evidence-based practice
In parallel, ISSCA will offer its international certification programs, providing physicians with structured training and global validation aligned with ISSCA’s educational standards.
A Platform for Collaboration and Regional Leadership
Beyond the academic program, the symposium will foster curated opportunities for professional interaction among physicians, faculty, and industry leaders. These environments are designed to encourage collaboration, exchange of clinical experience, and the formation of strategic alliances that extend well beyond the event itself.
ISSCA’s 11th Symposium in Buenos Aires exemplifies the organization’s role as a global platform where medical leaders converge to learn, connect, and advance regenerative medicine together.
The 11th ISSCA Symposium on Regenerative Medicine and Cellular Therapies – Argentina 2026 (July 10–11) represents a defining moment in ISSCA’s history in the country—honoring over a decade of collaboration while setting a new benchmark for scale, scientific excellence, and regional impact.
Physicians and healthcare professionals interested in attending can register at:
Early registration benefits include:
- Special Early-Bird pricing
- Priority access to certification programs
- Admission to MedConnect Brasil
- Pre-event educational materials and digital resources
About ISSCA
“The International Society for Stem Cell Application (ISSCA) is a leading organization in the field of regenerative medicine. It is dedicated to advancing the science and practice of stem cell therapy and regenerative medicine through education, certification, research, and training. ISSCA provides certification training in cities worldwide, recognizing the importance of standards and certifications in regenerative medicine as a medical specialty.”
About Global Stem Cells Group
“Global Stem Cells Group is a leading provider of regenerative medicine solutions, dedicated to advancing healthcare through innovative therapies. With a global presence and a multidisciplinary team of experts, the organization strives to harness the potential of stem cells and regenerative medicine to improve patient outcomes across various medical fields. Through its extensive network of clinics, research facilities, and training centers, Global Stem Cells Group is committed to pushing the boundaries of regenerative medicine and making a positive impact on global healthcare.”
Safe Harbor Statement
Statements in this news release may be “forward-looking statements.” Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business, partly based on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
